Whitehead · The American journal of clinical nutrition 2014 · systematic review and meta-analysis of randomized controlled trials · n=28 studies

Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials.

Level 1 - systematic review of randomized trials

Systematic review and meta-analysis of randomized controlled trials

PubMed 25411276 · doi:10.3945/ajcn.114.086108 · record verified 2026-08-26

What was done

Authors conducted a systematic review and random-effects meta-analysis of 28 randomized controlled trials (searched across PubMed, AGRICOLA, Scopus, and industry in-house reports from 1966 to 2013) to quantify the effect of ≥3 g/day of oat beta-glucan compared with control diets on serum cholesterol concentrations and potential effect modifiers.

What was found

Intake of ≥3 g/day oat beta-glucan significantly reduced LDL cholesterol by 0.25 mmol/L (95% CI: 0.20, 0.30; P < 0.0001) and total cholesterol by 0.30 mmol/L (95% CI: 0.24, 0.35; P < 0.0001). There was no significant effect on HDL cholesterol or triglycerides. Dose (range: 3.0–12.4 g/d) and duration (range: 2–12 weeks) did not alter outcomes. Greater LDL lowering occurred in participants with higher baseline LDL cholesterol, and stronger effects were observed in individuals with diabetes.

Why it matters

These findings reinforce established dietary health claims that consuming at least 3 g/day of oat soluble fiber meaningfully lowers circulating LDL and total cholesterol.

Limits

The total number of human participants across the 28 trials was not reported in the abstract. Interventions were short (2 to 12 weeks), searches included internal industry reports, and the diabetic subgroup analysis was based on few studies.